Cargando...
Current therapy of KRAS-mutant lung cancer
KRAS mutations are the most frequent gain-of-function alterations in patients with lung adenocarcinoma (LADC) in the Western world. Although they have been identified decades ago, prior efforts to target KRAS signaling with single-agent therapeutic approaches such as farnesyl transferase inhibitors,...
Gardado en:
| Publicado en: | Cancer Metastasis Rev |
|---|---|
| Main Authors: | , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Springer US
2020
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7680319/ https://ncbi.nlm.nih.gov/pubmed/32548736 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10555-020-09903-9 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|